ClinicalTrials.gg
CompletedNCT07373236EX-HYPOUpdated Apr 29, 2026

The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

An interventional study of exendin(9-39)amide and Saline (0.9% NaCl) in Type 1 Diabetes, sponsored by Asger Lund, MD. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Asger Lund, MD · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.

Enrollment
128th of 157
12 · median 40
Started
2026
with 8 others
No phase
83 of 196
12 open now
Registered
187th of 196
by date
Lead sponsor
4 of 196
Asger Lund, MD

Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 128th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2026, is one of 83 with no phase, and was the 187th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, or all of them as a file.
02

Study summary

Type 1 diabetes is a serious and burdensome disease that carries the risk of severe complications and premature death, partly due to low blood sugar, also called hypoglycaemia. This is a constant threat, as individuals with type 1 diabetes lack the body's natural safeguard against low blood sugar: the hormone glucagon, which is normally released from the pancreas.

Recent research in mice suggests that this missing safeguard may be due to an imbalance in the hormones released from different cells in the pancreas. More specifically, glucagon-like peptide-1 (GLP-1) appears to play a role in the lack of glucagon secretion. By blocking this hormone using the substance exendin(9-39)NH₂, normalization of glucagon release during low blood sugar has been observed in mice with type 1 diabetes.

The present study aims to investigate whether the same mechanism applies in humans with type 1 diabetes. If confirmed, this finding could form the basis for a novel adjunct treatment to insulin therapy and thereby potentially reduce the risk of hypoglycaemia in this patient group.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 diabetes
  • GLP-1
  • Exendin(9-39)NH2
  • Hypoglycemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian ethnicity
  • Age between 18 and 70 years
  • T1D (diagnosed according to the criteria of the World Health Organization) with \<69 mmol/mol (\<8.5%)
  • between 19 and 30 kg/m2
  • T1D duration of 2-30 years
  • C-peptide negative (5 gram arginine-stimulated C-peptide ≤100 pmol/l)
  • Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months

Exclusion criteria

Exclusion Criteria:

  • Anaemia ( below normal range)
  • Late microvascular complications except mild non-proliferative retinopathy
  • Liver disease (Evaluated by (ALAT) and/or aspartate aminotransferase (ASAT) >2 times normal values) or a history of hepatobiliary disorder
  • Kidney disease (serum creatinine above normal range)
  • Treatment with any glucose-lowering drugs beside insulin
  • Active or recent (within 5 years) malignant disease
  • Regular tobacco smoking or use of other nicotine-containing products
  • Any condition considered incompatible with participation by the investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Exendin(9-39)NH2

    GLP-1 antagonist

    Drug: exendin(9-39)amide

  • Placebo comparator
    Placebo

    Saline

    Drug: Saline (0.9% NaCl)

Interventions

06

What researchers measure

Primary outcomes

  1. bsAUC Glucagon

    Entire study periode

    Time frame: 0-135 minutes

Secondary outcomes

  1. bsAUC of Glucagon

    Primary endpoint

    Time frame: 30-90 minutes

  2. Total Glucose infused

    Recovery phase glucose infused

    Time frame: 90-135 minutes

  3. Glucose infused (entire period)

    Entire glucose infused

    Time frame: 0-135 minutes

  4. GLP-1

    Circulating GLP-1

    Time frame: 0-135 minutes

  5. Cortisol

    Cortisol

    Time frame: 0-135 minutes

07

Study locations

1 site
  • Gentofte Hospital
    Hellerup, 2100, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Apr 2026, 2 months.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 2 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Jan 28, 2026
StartActual
Jan 23, 2026
Primary completionActual
Apr 9, 2026
CompletionActual
Apr 9, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07373236
Lead sponsor
Asger Lund, MD
Responsible party
Asger Lund, MD (Associate professor, MD, Ph.D., University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
Jan 28, 2026
Start date
Jan 23, 2026
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update
Apr 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avexitide

Start the discussion